Trial Profile
A Phase I Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic Graft-versus-Host-Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions
- 22 Jun 2020 Status changed from active, no longer recruiting to completed.
- 24 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 10 Aug 2015 Status changed from suspended to recruiting as per ClinicalTrials.gov record.